Study Summary
This trial is testing a new treatment for prostate cancer that involves MR-guided radiotherapy. 40 patients will be recruited and monitored for up to 5 years.
Eligible Conditions
- Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Baseline to 5-year follow-up
Baseline
Feasibility of MR-guided Linear Acceleratorfor tumour-targeted intra-prostatic dose escalation as boost
Baseline to 5-year follow-up
Acute Toxicity
Late Toxicity
Patient-reported quality-of-life assessed by EPIC-26
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
MR-guided Tumour Boost with SBRT
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: MR-guided Radiotherapy Boost · No Placebo Group · N/A
MR-guided Tumour Boost with SBRT
Radiation
Experimental Group · 1 Intervention: MR-guided Radiotherapy Boost · Intervention Types: RadiationTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 5-year follow-up
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,386 Previous Clinical Trials
471,929 Total Patients Enrolled
62 Trials studying Prostate Cancer
15,332 Patients Enrolled for Prostate Cancer
Eligibility Criteria
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are scheduled to receive external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT).
References
Frequently Asked Questions
Are there any opportunities to enroll in this clinical research study at present?
"Contrary to popular belief, this clinical trial is not actively accepting patients. It was first listed on January 1st 2023 and the information was last revised on October 6th 2022. Despite this fact, there are still 1321 other trials seeking participants at present time." - Anonymous Online Contributor
Unverified Answer